Compare BXP & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXP | RGEN |
|---|---|---|
| Founded | 1970 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.6B |
| IPO Year | 1998 | 1995 |
| Metric | BXP | RGEN |
|---|---|---|
| Price | $58.06 | $116.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $71.83 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 1.8M | 839.1K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | ★ 1833.33 | 286.96 |
| EPS | ★ 1.74 | 0.86 |
| Revenue | ★ $3,482,279,000.00 | $141,236,000.00 |
| Revenue This Year | $11.00 | $14.30 |
| Revenue Next Year | $2.91 | $14.52 |
| P/E Ratio | ★ $33.41 | $137.66 |
| Revenue Growth | 2.19 | ★ 35.10 |
| 52 Week Low | $49.93 | $109.50 |
| 52 Week High | $79.33 | $175.77 |
| Indicator | BXP | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 42.70 |
| Support Level | $57.59 | $111.29 |
| Resistance Level | $59.88 | $130.12 |
| Average True Range (ATR) | 1.54 | 6.05 |
| MACD | 0.46 | -0.80 |
| Stochastic Oscillator | 78.84 | 21.62 |
BXP owns 179 properties consisting of approximately 52.6 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.